<h3>Background</h3> Certolizumab pegol (CZP) is a Pegylated, Fc free monoclonal antibody that is useful in different autoimmune conditions. It does not bind FcRn and is not expected to undergo transfer across the placenta and probably there is a minimal placenta transfer of CZP in humans. On the other hand, most chronic inflammatory diseases are prevalent in women and 50% of these diseases need active treatment. We describe our experience for more than 7 years in patients with inflammatory arthritis and pregnancy that received CZP. <h3>Objectives</h3> We describe our experience in patients with inflammatory artropathy that received CZP during their pregnancy. <h3>Methods</h3> We review our cohort of patients with Rheumatoid Arthritis, Spondyloarthritis and psoriatic arthritis from 2011 to 2017 that received CZP and analyzed those cases of pregnancy and described the clinical characteristic, the medication concomitant and the course of the pregnancy. <h3>Results</h3> We review more than 750 patients with inflammatory arthritis that received CZP and found 15 cases that was in pregnancy. See table 1. <h3>Conclusion</h3> CZP is a useful alternative of treatment for pregnant patients and with inflammatory arthropaties that required therapeutic agent. This topic has been recently review and show that this agent is safe for pregnant women and for those breastfeeding and support continuation of CZP during pregnancy, when considered necessary. There has been clear evidence during the last few years that this is the treatment of choice for women in fertile age with autoimmune diseases which requires immunomodulation. <h3>References</h3> [1] Mariette X., et al. Ann Rheum Dis2017.doi.10.1136/2017-212196. [2] Clowse MEB., et al. Arthritis Rheumatol 2017.69.suppl 100. Abstract 1309. <h3>Disclosure of Interests</h3> None declared